nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—lung cancer	0.155	1	CbGaD
Paroxetine—ABCB1—Topotecan—lung cancer	0.0251	0.0582	CbGbCtD
Paroxetine—CYP2B6—Irinotecan—lung cancer	0.0239	0.0554	CbGbCtD
Paroxetine—CYP2C9—Gefitinib—lung cancer	0.0237	0.0548	CbGbCtD
Paroxetine—ABCB1—Gefitinib—lung cancer	0.023	0.0532	CbGbCtD
Paroxetine—CYP2C9—Teniposide—lung cancer	0.023	0.0532	CbGbCtD
Paroxetine—CYP2D6—Gefitinib—lung cancer	0.0217	0.0501	CbGbCtD
Paroxetine—CYP2C8—Erlotinib—lung cancer	0.0201	0.0465	CbGbCtD
Paroxetine—CYP2B6—Cisplatin—lung cancer	0.0195	0.0452	CbGbCtD
Paroxetine—CYP2C8—Paclitaxel—lung cancer	0.0184	0.0425	CbGbCtD
Paroxetine—ABCB1—Vinorelbine—lung cancer	0.0177	0.041	CbGbCtD
Paroxetine—CYP2D6—Vinorelbine—lung cancer	0.0167	0.0386	CbGbCtD
Paroxetine—CYP2C8—Etoposide—lung cancer	0.0145	0.0336	CbGbCtD
Paroxetine—ABCB1—Crizotinib—lung cancer	0.0141	0.0326	CbGbCtD
Paroxetine—ABCB1—Gemcitabine—lung cancer	0.0138	0.0319	CbGbCtD
Paroxetine—ABCB1—Erlotinib—lung cancer	0.0136	0.0315	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—lung cancer	0.0131	0.0303	CbGbCtD
Paroxetine—CYP2C9—Paclitaxel—lung cancer	0.0128	0.0297	CbGbCtD
Paroxetine—CYP2D6—Erlotinib—lung cancer	0.0128	0.0296	CbGbCtD
Paroxetine—ABCB1—Paclitaxel—lung cancer	0.0124	0.0288	CbGbCtD
Paroxetine—ABCB1—Irinotecan—lung cancer	0.0123	0.0284	CbGbCtD
Paroxetine—ABCB1—Vinblastine—lung cancer	0.0109	0.0253	CbGbCtD
Paroxetine—CYP2C9—Cisplatin—lung cancer	0.0103	0.0239	CbGbCtD
Paroxetine—CYP2D6—Vinblastine—lung cancer	0.0103	0.0238	CbGbCtD
Paroxetine—ABCB1—Cisplatin—lung cancer	0.01	0.0232	CbGbCtD
Paroxetine—ABCB1—Etoposide—lung cancer	0.00983	0.0228	CbGbCtD
Paroxetine—ABCB1—Docetaxel—lung cancer	0.00899	0.0208	CbGbCtD
Paroxetine—HTR2A—phrenic nerve—lung cancer	0.00801	0.274	CbGeAlD
Paroxetine—ABCB1—Doxorubicin—lung cancer	0.0067	0.0155	CbGbCtD
Paroxetine—ABCB1—Methotrexate—lung cancer	0.00649	0.015	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—lung cancer	0.00632	0.0146	CbGbCtD
Paroxetine—HTR2A—pulmonary artery—lung cancer	0.00291	0.0995	CbGeAlD
Paroxetine—TACR1—respiratory system—lung cancer	0.00201	0.0686	CbGeAlD
Paroxetine—TACR1—trachea—lung cancer	0.00148	0.0507	CbGeAlD
Paroxetine—CHRM5—epithelium—lung cancer	0.00123	0.0422	CbGeAlD
Paroxetine—TACR1—lung—lung cancer	0.00107	0.0364	CbGeAlD
Paroxetine—SLC6A3—respiratory system—lung cancer	0.00101	0.0345	CbGeAlD
Paroxetine—CYP2C8—mammary gland—lung cancer	0.001	0.0343	CbGeAlD
Paroxetine—SLC6A4—respiratory system—lung cancer	0.000925	0.0316	CbGeAlD
Paroxetine—CYP2C9—mammary gland—lung cancer	0.000891	0.0305	CbGeAlD
Paroxetine—SLC6A2—respiratory system—lung cancer	0.000814	0.0279	CbGeAlD
Paroxetine—TACR1—lymph node—lung cancer	0.000729	0.0249	CbGeAlD
Paroxetine—CHRM1—trachea—lung cancer	0.000681	0.0233	CbGeAlD
Paroxetine—CYP2B6—respiratory system—lung cancer	0.0006	0.0205	CbGeAlD
Paroxetine—SLC6A3—lung—lung cancer	0.000536	0.0183	CbGeAlD
Paroxetine—CYP2B6—bronchus—lung cancer	0.000494	0.0169	CbGeAlD
Paroxetine—SLC6A4—lung—lung cancer	0.000491	0.0168	CbGeAlD
Paroxetine—HTR2A—respiratory system—lung cancer	0.000489	0.0167	CbGeAlD
Paroxetine—CHRM1—lung—lung cancer	0.000489	0.0167	CbGeAlD
Paroxetine—SLC6A2—lung—lung cancer	0.000432	0.0148	CbGeAlD
Paroxetine—HTR2A—epithelium—lung cancer	0.000409	0.014	CbGeAlD
Paroxetine—HTR2A—trachea—lung cancer	0.000362	0.0124	CbGeAlD
Paroxetine—ABCB1—respiratory system—lung cancer	0.000321	0.011	CbGeAlD
Paroxetine—CYP2B6—lung—lung cancer	0.000319	0.0109	CbGeAlD
Paroxetine—SLC6A2—lymph node—lung cancer	0.000296	0.0101	CbGeAlD
Paroxetine—ABCB1—epithelium—lung cancer	0.000268	0.00917	CbGeAlD
Paroxetine—HTR2A—lung—lung cancer	0.00026	0.00889	CbGeAlD
Paroxetine—ABCB1—trachea—lung cancer	0.000237	0.00811	CbGeAlD
Paroxetine—ABCB1—bone marrow—lung cancer	0.000188	0.00643	CbGeAlD
Paroxetine—ABCB1—lung—lung cancer	0.00017	0.00582	CbGeAlD
Paroxetine—ABCB1—lymph node—lung cancer	0.000116	0.00398	CbGeAlD
Paroxetine—Anaphylactic shock—Docetaxel—lung cancer	4.92e-05	0.000183	CcSEcCtD
Paroxetine—Oedema—Docetaxel—lung cancer	4.92e-05	0.000183	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—lung cancer	4.91e-05	0.000183	CcSEcCtD
Paroxetine—Pruritus—Gemcitabine—lung cancer	4.9e-05	0.000183	CcSEcCtD
Paroxetine—Infection—Docetaxel—lung cancer	4.88e-05	0.000182	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—lung cancer	4.88e-05	0.000182	CcSEcCtD
Paroxetine—Feeling abnormal—Etoposide—lung cancer	4.87e-05	0.000182	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—lung cancer	4.87e-05	0.000182	CcSEcCtD
Paroxetine—Diarrhoea—Irinotecan—lung cancer	4.87e-05	0.000182	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—lung cancer	4.84e-05	0.000181	CcSEcCtD
Paroxetine—Gastrointestinal pain—Etoposide—lung cancer	4.84e-05	0.00018	CcSEcCtD
Paroxetine—Shock—Docetaxel—lung cancer	4.84e-05	0.00018	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—lung cancer	4.82e-05	0.00018	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—lung cancer	4.81e-05	0.00018	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—lung cancer	4.81e-05	0.000179	CcSEcCtD
Paroxetine—Visual impairment—Methotrexate—lung cancer	4.81e-05	0.000179	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—lung cancer	4.8e-05	0.000179	CcSEcCtD
Paroxetine—Feeling abnormal—Paclitaxel—lung cancer	4.78e-05	0.000178	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—lung cancer	4.77e-05	0.000178	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	4.77e-05	0.000178	CcSEcCtD
Paroxetine—Hypersensitivity—Cisplatin—lung cancer	4.76e-05	0.000178	CcSEcCtD
Paroxetine—Gastrointestinal pain—Paclitaxel—lung cancer	4.74e-05	0.000177	CcSEcCtD
Paroxetine—Diarrhoea—Gemcitabine—lung cancer	4.74e-05	0.000177	CcSEcCtD
Paroxetine—Erythema multiforme—Methotrexate—lung cancer	4.71e-05	0.000176	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—lung cancer	4.71e-05	0.000176	CcSEcCtD
Paroxetine—Dizziness—Irinotecan—lung cancer	4.7e-05	0.000175	CcSEcCtD
Paroxetine—Urticaria—Etoposide—lung cancer	4.7e-05	0.000175	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—lung cancer	4.69e-05	0.000175	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—lung cancer	4.69e-05	0.000175	CcSEcCtD
Paroxetine—Abdominal pain—Etoposide—lung cancer	4.68e-05	0.000174	CcSEcCtD
Paroxetine—Body temperature increased—Etoposide—lung cancer	4.68e-05	0.000174	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—lung cancer	4.68e-05	0.000174	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—lung cancer	4.68e-05	0.000174	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—lung cancer	4.66e-05	0.000174	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—lung cancer	4.65e-05	0.000174	CcSEcCtD
Paroxetine—Asthenia—Cisplatin—lung cancer	4.63e-05	0.000173	CcSEcCtD
Paroxetine—Cardiac disorder—Methotrexate—lung cancer	4.63e-05	0.000173	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—lung cancer	4.61e-05	0.000172	CcSEcCtD
Paroxetine—Urticaria—Paclitaxel—lung cancer	4.61e-05	0.000172	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—lung cancer	4.59e-05	0.000171	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—lung cancer	4.59e-05	0.000171	CcSEcCtD
Paroxetine—Abdominal pain—Paclitaxel—lung cancer	4.58e-05	0.000171	CcSEcCtD
Paroxetine—Body temperature increased—Paclitaxel—lung cancer	4.58e-05	0.000171	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—lung cancer	4.55e-05	0.00017	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—lung cancer	4.54e-05	0.000169	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—lung cancer	4.52e-05	0.000169	CcSEcCtD
Paroxetine—Vomiting—Irinotecan—lung cancer	4.52e-05	0.000169	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—lung cancer	4.51e-05	0.000168	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—lung cancer	4.5e-05	0.000168	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—lung cancer	4.49e-05	0.000168	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—lung cancer	4.49e-05	0.000168	CcSEcCtD
Paroxetine—Rash—Irinotecan—lung cancer	4.48e-05	0.000167	CcSEcCtD
Paroxetine—Dermatitis—Irinotecan—lung cancer	4.48e-05	0.000167	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Docetaxel—lung cancer	4.48e-05	0.000167	CcSEcCtD
Paroxetine—Chills—Methotrexate—lung cancer	4.47e-05	0.000167	CcSEcCtD
Paroxetine—Headache—Irinotecan—lung cancer	4.45e-05	0.000166	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—lung cancer	4.45e-05	0.000166	CcSEcCtD
Paroxetine—Diarrhoea—Cisplatin—lung cancer	4.42e-05	0.000165	CcSEcCtD
Paroxetine—Paraesthesia—Docetaxel—lung cancer	4.41e-05	0.000165	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—lung cancer	4.41e-05	0.000164	CcSEcCtD
Paroxetine—Vomiting—Gemcitabine—lung cancer	4.4e-05	0.000164	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—lung cancer	4.4e-05	0.000164	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—lung cancer	4.38e-05	0.000164	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—lung cancer	4.37e-05	0.000163	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—lung cancer	4.37e-05	0.000163	CcSEcCtD
Paroxetine—Rash—Gemcitabine—lung cancer	4.37e-05	0.000163	CcSEcCtD
Paroxetine—Dermatitis—Gemcitabine—lung cancer	4.36e-05	0.000163	CcSEcCtD
Paroxetine—Hypersensitivity—Etoposide—lung cancer	4.36e-05	0.000163	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—lung cancer	4.34e-05	0.000162	CcSEcCtD
Paroxetine—Erythema—Methotrexate—lung cancer	4.34e-05	0.000162	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—lung cancer	4.34e-05	0.000162	CcSEcCtD
Paroxetine—Headache—Gemcitabine—lung cancer	4.34e-05	0.000162	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—lung cancer	4.33e-05	0.000162	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—lung cancer	4.33e-05	0.000161	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—lung cancer	4.32e-05	0.000161	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—lung cancer	4.32e-05	0.000161	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—lung cancer	4.3e-05	0.00016	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—lung cancer	4.29e-05	0.00016	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—lung cancer	4.27e-05	0.000159	CcSEcCtD
Paroxetine—Hypersensitivity—Paclitaxel—lung cancer	4.27e-05	0.000159	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—lung cancer	4.25e-05	0.000159	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—lung cancer	4.25e-05	0.000159	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—lung cancer	4.24e-05	0.000158	CcSEcCtD
Paroxetine—Asthenia—Etoposide—lung cancer	4.24e-05	0.000158	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—lung cancer	4.24e-05	0.000158	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—lung cancer	4.24e-05	0.000158	CcSEcCtD
Paroxetine—Nausea—Irinotecan—lung cancer	4.22e-05	0.000158	CcSEcCtD
Paroxetine—Pain—Docetaxel—lung cancer	4.2e-05	0.000157	CcSEcCtD
Paroxetine—Constipation—Docetaxel—lung cancer	4.2e-05	0.000157	CcSEcCtD
Paroxetine—Back pain—Methotrexate—lung cancer	4.2e-05	0.000157	CcSEcCtD
Paroxetine—Pruritus—Etoposide—lung cancer	4.18e-05	0.000156	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—lung cancer	4.16e-05	0.000155	CcSEcCtD
Paroxetine—Asthenia—Paclitaxel—lung cancer	4.16e-05	0.000155	CcSEcCtD
Paroxetine—Nausea—Gemcitabine—lung cancer	4.11e-05	0.000154	CcSEcCtD
Paroxetine—Vomiting—Cisplatin—lung cancer	4.1e-05	0.000153	CcSEcCtD
Paroxetine—Pruritus—Paclitaxel—lung cancer	4.1e-05	0.000153	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—lung cancer	4.09e-05	0.000153	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—lung cancer	4.08e-05	0.000152	CcSEcCtD
Paroxetine—Rash—Cisplatin—lung cancer	4.07e-05	0.000152	CcSEcCtD
Paroxetine—Dermatitis—Cisplatin—lung cancer	4.07e-05	0.000152	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—lung cancer	4.05e-05	0.000151	CcSEcCtD
Paroxetine—Diarrhoea—Etoposide—lung cancer	4.05e-05	0.000151	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—lung cancer	4.04e-05	0.000151	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—lung cancer	4.03e-05	0.00015	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—lung cancer	4.03e-05	0.00015	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—lung cancer	4.02e-05	0.00015	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—lung cancer	4.01e-05	0.00015	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—lung cancer	4.01e-05	0.00015	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—lung cancer	4.01e-05	0.00015	CcSEcCtD
Paroxetine—Diarrhoea—Paclitaxel—lung cancer	3.97e-05	0.000148	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—lung cancer	3.92e-05	0.000146	CcSEcCtD
Paroxetine—Malaise—Methotrexate—lung cancer	3.91e-05	0.000146	CcSEcCtD
Paroxetine—Dizziness—Etoposide—lung cancer	3.91e-05	0.000146	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—lung cancer	3.9e-05	0.000146	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—lung cancer	3.9e-05	0.000146	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—lung cancer	3.89e-05	0.000145	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—lung cancer	3.89e-05	0.000145	CcSEcCtD
Paroxetine—Body temperature increased—Docetaxel—lung cancer	3.89e-05	0.000145	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—lung cancer	3.89e-05	0.000145	CcSEcCtD
Paroxetine—Chills—Doxorubicin—lung cancer	3.87e-05	0.000145	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—lung cancer	3.86e-05	0.000144	CcSEcCtD
Paroxetine—Dizziness—Paclitaxel—lung cancer	3.83e-05	0.000143	CcSEcCtD
Paroxetine—Nausea—Cisplatin—lung cancer	3.83e-05	0.000143	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—lung cancer	3.82e-05	0.000142	CcSEcCtD
Paroxetine—Cough—Methotrexate—lung cancer	3.79e-05	0.000141	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—lung cancer	3.78e-05	0.000141	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—lung cancer	3.76e-05	0.00014	CcSEcCtD
Paroxetine—Vomiting—Etoposide—lung cancer	3.76e-05	0.00014	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—lung cancer	3.76e-05	0.00014	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—lung cancer	3.76e-05	0.00014	CcSEcCtD
Paroxetine—Rash—Etoposide—lung cancer	3.73e-05	0.000139	CcSEcCtD
Paroxetine—Dermatitis—Etoposide—lung cancer	3.73e-05	0.000139	CcSEcCtD
Paroxetine—Headache—Etoposide—lung cancer	3.71e-05	0.000138	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—lung cancer	3.7e-05	0.000138	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—lung cancer	3.7e-05	0.000138	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—lung cancer	3.7e-05	0.000138	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—lung cancer	3.7e-05	0.000138	CcSEcCtD
Paroxetine—Tension—Doxorubicin—lung cancer	3.69e-05	0.000138	CcSEcCtD
Paroxetine—Vomiting—Paclitaxel—lung cancer	3.69e-05	0.000138	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—lung cancer	3.68e-05	0.000137	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.67e-05	0.000137	CcSEcCtD
Paroxetine—Rash—Paclitaxel—lung cancer	3.66e-05	0.000136	CcSEcCtD
Paroxetine—Dermatitis—Paclitaxel—lung cancer	3.65e-05	0.000136	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—lung cancer	3.65e-05	0.000136	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—lung cancer	3.65e-05	0.000136	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—lung cancer	3.64e-05	0.000136	CcSEcCtD
Paroxetine—Headache—Paclitaxel—lung cancer	3.63e-05	0.000136	CcSEcCtD
Paroxetine—Hypersensitivity—Docetaxel—lung cancer	3.62e-05	0.000135	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—lung cancer	3.61e-05	0.000135	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—lung cancer	3.57e-05	0.000133	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—lung cancer	3.54e-05	0.000132	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—lung cancer	3.54e-05	0.000132	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—lung cancer	3.53e-05	0.000132	CcSEcCtD
Paroxetine—Infection—Methotrexate—lung cancer	3.52e-05	0.000131	CcSEcCtD
Paroxetine—Nausea—Etoposide—lung cancer	3.51e-05	0.000131	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—lung cancer	3.49e-05	0.00013	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—lung cancer	3.48e-05	0.00013	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—lung cancer	3.47e-05	0.00013	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—lung cancer	3.47e-05	0.00013	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—lung cancer	3.47e-05	0.000129	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—lung cancer	3.45e-05	0.000129	CcSEcCtD
Paroxetine—Nausea—Paclitaxel—lung cancer	3.44e-05	0.000129	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—lung cancer	3.44e-05	0.000128	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—lung cancer	3.42e-05	0.000128	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—lung cancer	3.39e-05	0.000126	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—lung cancer	3.38e-05	0.000126	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—lung cancer	3.37e-05	0.000126	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—lung cancer	3.36e-05	0.000126	CcSEcCtD
Paroxetine—Diarrhoea—Docetaxel—lung cancer	3.36e-05	0.000126	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—lung cancer	3.32e-05	0.000124	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—lung cancer	3.31e-05	0.000124	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—lung cancer	3.3e-05	0.000123	CcSEcCtD
Paroxetine—Cough—Doxorubicin—lung cancer	3.28e-05	0.000122	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—lung cancer	3.26e-05	0.000122	CcSEcCtD
Paroxetine—Dizziness—Docetaxel—lung cancer	3.25e-05	0.000121	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—lung cancer	3.25e-05	0.000121	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—lung cancer	3.23e-05	0.00012	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—lung cancer	3.2e-05	0.00012	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—lung cancer	3.2e-05	0.000119	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—lung cancer	3.2e-05	0.000119	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—lung cancer	3.2e-05	0.000119	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—lung cancer	3.19e-05	0.000119	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—lung cancer	3.18e-05	0.000119	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.18e-05	0.000119	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—lung cancer	3.16e-05	0.000118	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—lung cancer	3.16e-05	0.000118	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—lung cancer	3.15e-05	0.000118	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—lung cancer	3.13e-05	0.000117	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—lung cancer	3.13e-05	0.000117	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—lung cancer	3.12e-05	0.000116	CcSEcCtD
Paroxetine—Rash—Docetaxel—lung cancer	3.1e-05	0.000116	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—lung cancer	3.1e-05	0.000116	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—lung cancer	3.09e-05	0.000115	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—lung cancer	3.08e-05	0.000115	CcSEcCtD
Paroxetine—Headache—Docetaxel—lung cancer	3.08e-05	0.000115	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—lung cancer	3.07e-05	0.000114	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—lung cancer	3.07e-05	0.000114	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—lung cancer	3.06e-05	0.000114	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—lung cancer	3.05e-05	0.000114	CcSEcCtD
Paroxetine—Infection—Doxorubicin—lung cancer	3.05e-05	0.000114	CcSEcCtD
Paroxetine—Pain—Methotrexate—lung cancer	3.03e-05	0.000113	CcSEcCtD
Paroxetine—Shock—Doxorubicin—lung cancer	3.02e-05	0.000113	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—lung cancer	3.01e-05	0.000112	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—lung cancer	3e-05	0.000112	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—lung cancer	2.99e-05	0.000112	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—lung cancer	2.98e-05	0.000111	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—lung cancer	2.97e-05	0.000111	CcSEcCtD
Paroxetine—Nausea—Docetaxel—lung cancer	2.92e-05	0.000109	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—lung cancer	2.92e-05	0.000109	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—lung cancer	2.9e-05	0.000108	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—lung cancer	2.87e-05	0.000107	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—lung cancer	2.81e-05	0.000105	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—lung cancer	2.8e-05	0.000105	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—lung cancer	2.8e-05	0.000105	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.79e-05	0.000104	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—lung cancer	2.77e-05	0.000104	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—lung cancer	2.75e-05	0.000103	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—lung cancer	2.73e-05	0.000102	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—lung cancer	2.73e-05	0.000102	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—lung cancer	2.7e-05	0.000101	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—lung cancer	2.67e-05	9.95e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—lung cancer	2.65e-05	9.88e-05	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—lung cancer	2.64e-05	9.87e-05	CcSEcCtD
Paroxetine—Pain—Doxorubicin—lung cancer	2.62e-05	9.79e-05	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—lung cancer	2.62e-05	9.79e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—lung cancer	2.61e-05	9.74e-05	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—lung cancer	2.54e-05	9.49e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—lung cancer	2.53e-05	9.43e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—lung cancer	2.51e-05	9.36e-05	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—lung cancer	2.51e-05	9.35e-05	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—lung cancer	2.44e-05	9.09e-05	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—lung cancer	2.43e-05	9.05e-05	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—lung cancer	2.43e-05	9.05e-05	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—lung cancer	2.42e-05	9.05e-05	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—lung cancer	2.34e-05	8.74e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—lung cancer	2.26e-05	8.43e-05	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—lung cancer	2.25e-05	8.41e-05	CcSEcCtD
Paroxetine—Rash—Methotrexate—lung cancer	2.23e-05	8.34e-05	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—lung cancer	2.23e-05	8.33e-05	CcSEcCtD
Paroxetine—Headache—Methotrexate—lung cancer	2.22e-05	8.28e-05	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—lung cancer	2.2e-05	8.21e-05	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—lung cancer	2.17e-05	8.1e-05	CcSEcCtD
Paroxetine—Nausea—Methotrexate—lung cancer	2.1e-05	7.85e-05	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—lung cancer	2.1e-05	7.83e-05	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—lung cancer	2.03e-05	7.57e-05	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—lung cancer	1.95e-05	7.28e-05	CcSEcCtD
Paroxetine—Rash—Doxorubicin—lung cancer	1.93e-05	7.22e-05	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—lung cancer	1.93e-05	7.21e-05	CcSEcCtD
Paroxetine—Headache—Doxorubicin—lung cancer	1.92e-05	7.17e-05	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—lung cancer	1.82e-05	6.8e-05	CcSEcCtD
Paroxetine—CHRM1—Signaling Pathways—IL6R—lung cancer	4.86e-06	4.18e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—lung cancer	4.85e-06	4.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CREBBP—lung cancer	4.85e-06	4.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6R—lung cancer	4.84e-06	4.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CREBBP—lung cancer	4.83e-06	4.16e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—lung cancer	4.8e-06	4.13e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6R—lung cancer	4.79e-06	4.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—lung cancer	4.79e-06	4.13e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CREBBP—lung cancer	4.79e-06	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—lung cancer	4.78e-06	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—lung cancer	4.77e-06	4.11e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.76e-06	4.1e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—lung cancer	4.76e-06	4.1e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—lung cancer	4.76e-06	4.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—lung cancer	4.75e-06	4.09e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—lung cancer	4.73e-06	4.08e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ERCC2—lung cancer	4.72e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—lung cancer	4.72e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—lung cancer	4.72e-06	4.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—lung cancer	4.7e-06	4.05e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—lung cancer	4.69e-06	4.04e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ERCC2—lung cancer	4.68e-06	4.03e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—lung cancer	4.66e-06	4.01e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAP2K1—lung cancer	4.65e-06	4.01e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—lung cancer	4.64e-06	4e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAP2K1—lung cancer	4.63e-06	3.99e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—lung cancer	4.62e-06	3.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAP2K1—lung cancer	4.61e-06	3.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—lung cancer	4.6e-06	3.96e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—lung cancer	4.59e-06	3.96e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—lung cancer	4.58e-06	3.95e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—lung cancer	4.58e-06	3.95e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	4.58e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAP2K1—lung cancer	4.57e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—lung cancer	4.56e-06	3.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	4.55e-06	3.92e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—lung cancer	4.54e-06	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	4.54e-06	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—lung cancer	4.54e-06	3.91e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—lung cancer	4.53e-06	3.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—lung cancer	4.5e-06	3.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	4.5e-06	3.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—lung cancer	4.49e-06	3.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—lung cancer	4.44e-06	3.83e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—lung cancer	4.44e-06	3.83e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—lung cancer	4.4e-06	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—lung cancer	4.39e-06	3.78e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—lung cancer	4.39e-06	3.78e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOA1—lung cancer	4.33e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—lung cancer	4.32e-06	3.72e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—lung cancer	4.27e-06	3.68e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CREBBP—lung cancer	4.21e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—lung cancer	4.2e-06	3.62e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—lung cancer	4.17e-06	3.6e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	4.16e-06	3.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—lung cancer	4.14e-06	3.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	4.14e-06	3.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—lung cancer	4.13e-06	3.56e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAF1—lung cancer	4.13e-06	3.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	4.12e-06	3.55e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—lung cancer	4.12e-06	3.55e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—lung cancer	4.11e-06	3.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—lung cancer	4.11e-06	3.54e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAF1—lung cancer	4.1e-06	3.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAF1—lung cancer	4.09e-06	3.53e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—lung cancer	4.09e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOA1—lung cancer	4.08e-06	3.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—lung cancer	4.08e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	4.08e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—lung cancer	4.07e-06	3.51e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—lung cancer	4.07e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—lung cancer	4.06e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAF1—lung cancer	4.05e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOA1—lung cancer	4.05e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—lung cancer	4.05e-06	3.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	4.03e-06	3.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—lung cancer	4.03e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—lung cancer	4.01e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—lung cancer	4.01e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—lung cancer	4.01e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—lung cancer	4e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—lung cancer	4e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—lung cancer	4e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—lung cancer	3.99e-06	3.44e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—lung cancer	3.96e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—lung cancer	3.96e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—lung cancer	3.96e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—lung cancer	3.94e-06	3.4e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—lung cancer	3.94e-06	3.4e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—lung cancer	3.94e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.88e-06	3.34e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—lung cancer	3.87e-06	3.34e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—lung cancer	3.85e-06	3.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—lung cancer	3.85e-06	3.31e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—lung cancer	3.84e-06	3.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—lung cancer	3.83e-06	3.3e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—lung cancer	3.81e-06	3.29e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—lung cancer	3.8e-06	3.28e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—lung cancer	3.78e-06	3.25e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—lung cancer	3.78e-06	3.25e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—lung cancer	3.77e-06	3.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	3.74e-06	3.22e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—lung cancer	3.73e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—lung cancer	3.72e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—lung cancer	3.71e-06	3.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—lung cancer	3.71e-06	3.19e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—lung cancer	3.7e-06	3.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—lung cancer	3.7e-06	3.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—lung cancer	3.69e-06	3.18e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—lung cancer	3.68e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—lung cancer	3.68e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—lung cancer	3.67e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—lung cancer	3.67e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—lung cancer	3.67e-06	3.16e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CREBBP—lung cancer	3.67e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—lung cancer	3.66e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—lung cancer	3.65e-06	3.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—lung cancer	3.64e-06	3.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—lung cancer	3.63e-06	3.13e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—lung cancer	3.62e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—lung cancer	3.62e-06	3.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—lung cancer	3.61e-06	3.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—lung cancer	3.6e-06	3.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—lung cancer	3.59e-06	3.09e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—lung cancer	3.58e-06	3.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—lung cancer	3.58e-06	3.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—lung cancer	3.57e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—lung cancer	3.55e-06	3.06e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—lung cancer	3.55e-06	3.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—lung cancer	3.54e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—lung cancer	3.53e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—lung cancer	3.52e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—lung cancer	3.51e-06	3.02e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—lung cancer	3.5e-06	3.02e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	3.49e-06	3.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—lung cancer	3.48e-06	3e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—lung cancer	3.48e-06	3e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—lung cancer	3.48e-06	3e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—lung cancer	3.48e-06	3e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—lung cancer	3.47e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	3.47e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—lung cancer	3.47e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—lung cancer	3.46e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	3.46e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CREBBP—lung cancer	3.46e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—lung cancer	3.45e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—lung cancer	3.45e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—lung cancer	3.44e-06	2.96e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—lung cancer	3.43e-06	2.96e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CREBBP—lung cancer	3.43e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	3.43e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—lung cancer	3.42e-06	2.95e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—lung cancer	3.4e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—lung cancer	3.39e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—lung cancer	3.38e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—lung cancer	3.37e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—lung cancer	3.36e-06	2.89e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—lung cancer	3.35e-06	2.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—lung cancer	3.34e-06	2.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—lung cancer	3.32e-06	2.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—lung cancer	3.3e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—lung cancer	3.29e-06	2.84e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—lung cancer	3.28e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—lung cancer	3.26e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—lung cancer	3.25e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—lung cancer	3.24e-06	2.79e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—lung cancer	3.23e-06	2.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—lung cancer	3.21e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—lung cancer	3.21e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—lung cancer	3.21e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—lung cancer	3.21e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—lung cancer	3.2e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—lung cancer	3.17e-06	2.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—lung cancer	3.14e-06	2.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—lung cancer	3.13e-06	2.69e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—lung cancer	3.12e-06	2.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—lung cancer	3.11e-06	2.68e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—lung cancer	3.11e-06	2.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—lung cancer	3.1e-06	2.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—lung cancer	3.09e-06	2.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—lung cancer	3.09e-06	2.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—lung cancer	3.09e-06	2.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—lung cancer	3.08e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—lung cancer	3.07e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—lung cancer	3.06e-06	2.63e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—lung cancer	3.05e-06	2.63e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—lung cancer	3.03e-06	2.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—lung cancer	3.01e-06	2.59e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—lung cancer	3e-06	2.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—lung cancer	2.98e-06	2.56e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—lung cancer	2.96e-06	2.55e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—lung cancer	2.96e-06	2.55e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—lung cancer	2.95e-06	2.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—lung cancer	2.92e-06	2.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—lung cancer	2.91e-06	2.51e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—lung cancer	2.89e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—lung cancer	2.88e-06	2.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—lung cancer	2.87e-06	2.47e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—lung cancer	2.87e-06	2.47e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—lung cancer	2.86e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—lung cancer	2.84e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—lung cancer	2.83e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—lung cancer	2.83e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—lung cancer	2.83e-06	2.44e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—lung cancer	2.83e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—lung cancer	2.82e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—lung cancer	2.81e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—lung cancer	2.81e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—lung cancer	2.78e-06	2.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—lung cancer	2.67e-06	2.3e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—lung cancer	2.66e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—lung cancer	2.65e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—lung cancer	2.63e-06	2.26e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—lung cancer	2.62e-06	2.26e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—lung cancer	2.51e-06	2.16e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—lung cancer	2.5e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—lung cancer	2.47e-06	2.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	2.46e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—lung cancer	2.45e-06	2.11e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	2.44e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	2.44e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	2.41e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—lung cancer	2.38e-06	2.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—lung cancer	2.38e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—lung cancer	2.36e-06	2.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—lung cancer	2.36e-06	2.03e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—lung cancer	2.35e-06	2.03e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—lung cancer	2.33e-06	2.01e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—lung cancer	2.33e-06	2.01e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—lung cancer	2.27e-06	1.96e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—lung cancer	2.26e-06	1.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—lung cancer	2.25e-06	1.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—lung cancer	2.23e-06	1.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—lung cancer	2.18e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—lung cancer	2.16e-06	1.86e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—lung cancer	2.16e-06	1.86e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—lung cancer	2.14e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—lung cancer	2.12e-06	1.83e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—lung cancer	2.05e-06	1.76e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—lung cancer	2.01e-06	1.73e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—lung cancer	2e-06	1.72e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—lung cancer	1.99e-06	1.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—lung cancer	1.97e-06	1.7e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—lung cancer	1.85e-06	1.59e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.74e-06	1.5e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—lung cancer	1.73e-06	1.49e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—lung cancer	1.73e-06	1.49e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—lung cancer	1.51e-06	1.3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—lung cancer	1.42e-06	1.23e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—lung cancer	1.41e-06	1.22e-05	CbGpPWpGaD
